NCL Method ITA-18
Human Leukocyte Proliferation Assay (HuLa)
Listed in Datasets | publication by group NCL Protocols
Version 1.0 - published on 04 May 2020 doi:10.17917/C59D-T717 - cite this Last public release: 2.0b
Licensed under these terms
Description
Immunosuppression is a common reason for drug withdrawal from the market. Traditional immune function tests used to estimate a material’s immunosuppression is T-cell dependent antibody response (TDAR). This method involves a 28 day in vivo study evaluating an animal’s antibody titer to a known antigen (KLH) with and without challenge. Due to the limited quantities of novel drug candidates, an in vitro method called Human Leukocyte activation (HuLa) has been developed as a substitute for the traditional TDAR assay during early preclinical evaluation. The method presented herein is based on the HuLa assay originally developed by Mark Collinge, et al at Pfizer [1]. The protocol presented in this document has been adapted for use with engineered nanomaterials.
Content List
- NCL_Method_ITA-18_Sept2015.pdf(PDF | 162 KB)
Cite this work
Researchers should cite this work as follows:
- Timothy Potter, Barry Neun, Sarah Skoczen, Anna Ilinskaya, Marina Dobrovolskaia (2020). NCL Method ITA-18. NCI Hub. doi:10.17917/C59D-T717
Tags
NCL Protocols
This publication belongs to the NCL Protocols group.
When watching a publication, you will be notified when a new version is released.